Blood substitutes: Fluids, drugs, or miracle solutions?

Anesthesia and Analgesia

Volumn 82, Issue 2, 1996, Pages 390-405

  Dietz, Niki M ^a   Joyner, Michael J ^a   Warner, Mark A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROCARBON;

BLOOD SUBSTITUTION; BLOOD TRANSFUSION; ENCAPSULATION; HEMORRHAGIC SHOCK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOVOLEMIA; OXYGEN CONSUMPTION; PARENTERAL NUTRITION; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

ANIMALS; BLOOD SUBSTITUTES; FLUOROCARBONS; HEMODILUTION; HEMOGLOBINS; HUMANS; LIPOSOMES;

EID: 0030041349     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199602000-00032     Document Type: Review

References (201)

1. Amberson WR, Mulder AG, Steggerda FR, et al. Mammalian life without red blood corpuscles. Science 1933;78:106-7.
2. Von Starck. Ueber haemoglobininjectionen. Muench Med Wochenschr 1898;xiv:69 and 113.
3. Sellards AW, Minot GR. Injection of hemoglobin in man and its relation to blood destruction, with especial reference to the anemias. J Med Res 1916;34:469-94.
4. Whipple GH, Smith HP, Belt AE. Shock as a manifestation of tissue injury following rapid plasma protein depletion. Am J Physiol 1920;52:72-100.
5. Aub JC. Studies in experimental traumatic shock. I. The basal metabolism. Am J Physiol 1921;54:388-407.
6. Craig RL, Poole GV. Resuscitation in uncontrolled hemorrhage. Am Surg 1994;60:59-62.
7. Phillips GR, Kauder DR, Schwab CW. Massive blood loss in trauma patients. The benefits and dangers of transfusion therapy. Postgrad Med 1994;95:61-72.
8. Bickell WH, Wall MJ, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:1105-9.
9. Jacobs LM. Timing of fluid resuscitation in trauma. N Engl J Med 1994;331:1153-4.
10. Winslow RM. Blood substitutes - minireview. In: Brewer GJ, ed. The red cell: Seventh Ann Arbor Conference. Prog Clin Biol Res 1989;319:305-23.
11. Webster NR. Battlefield transfusions. JAMA 1994;271:319
12. Winslow RM. Red cell substitutes: current status, 1992. In: Nance SJ, ed. Blood safety: current challenges. Bethesda, MD: American Association of Blood Banks, 1992:151-67.
13. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994;34:464-70.
14. Surgenor DM, Wallace EL, Hao SHS, Chapman RH. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990;322:1646-51.
15. Cook SS, Epps J. Transfusion practice in Central Virginia. Transfusion 1991;31:355-60.
16. Wallace EL, Surgenor DM, Hao HS, et al. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion 1993;33:139-44.
17. Projections of the population of the United States by age, sex and race: 1988-2080. Current population reports, series P-24, No. 1018. Government Printing Office: US Bureau of the Census; 1989.
18. Perioperative Red Blood Cell Transfusion - Consensus Conference. JAMA 1988;260:2700-3.
19. American Society of Anesthesiologists. Questions and answers about transfusion practices. 2nd ed. Chicago: American Society of Anesthesiologists, 1992:15-16.
20. Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med 1989;321:941-6.
21. Busch MP, Eble BE, Khayam-Bashi H, et al. Evaluation of screened blood donations for human immunodeficiency virsus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 1991;325:1-5.
22. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
23. Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994;34:283-9.
24. Selik RM, Ward JW, Buehler JW. Demographic differences in cumulative incidence rates of transfusion-associated acquired immunodeficiency syndrome. Am J Epidemiol 1994;140:105-12.
25. Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-20.
26. Pindyck J, Avorn J, Kuriyan M, et al. Blood donation by the elderly. Clinical and policy considerations. JAMA 1987;257:1186-8.
27. American Association of Blood Banks. Technical manual. 10th ed. Arlington, VA: American Association of Blood Banks, 1990.
28. Schriemer PA, Longnecker DE, Mintz PD. The possible immunosuppressive effects of perioperative blood transfusion in cancer patients. Anesthesiology 1988;68:422-28.
29. Biro GP, Blais P, Rosen AL. Perfluorocarbon blood substitutes. Crit Rev Oncol Hematol 1987;6:311-74.
30. Graham JD. Injuries from traffic crashes: meeting the challenge. Annu Rev Publ Health 1993;14:515-43.
31. Birkmeyer JD, Goodnough LT, AuBuchon JP, et al. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993;33:544-51.
32. Birkmeyer JD, AuBuchon JP, Littenberg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg 1994;57:161-9.
33. Amberson WR, Flexner J, Steggerda FR, et al. On the use of Ringer-Locke solutions containing hemoglobin as a substitute for normal blood in mammals. J Cell Comp Physiol 1934;5:359-82.
34. Amberson WR, Jennings JJ, Rhode CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol 1949;1:469-89.
35. Bunn HE. Subunit dissociation of certain abnormal human hemoglobins. J Clin Invest 1969;48:126-38.
36. Bunn HE, Esham WT, Bull RW. The renal handling of hemoglobin. I. Glomerular filtration. J Exp Med 1969;129:909-23.
37. Bunn HE, Jandl JH. The renal handling of hemoglobin. E. Catabolism. J Exp Med 1969;129:925-34.
38. DeVenuto F, Friedman HI, Neville JR, Peck CC. Appraisal of hemoglobin solution as a blood substitute. Surg Gynecol Obstet 1979;149:417-36.
39. Baker SBdeC, Dawes RLF. Experimental haemoglobinuric nephrosis. J Pathol Bacteriol 1964;87:49-56.
40. Rabiner SF, Rosenfeld S. Role of intravascular hemolysis and the reticuloendothelial system in the production of hypercoagulable state. J Lab Clin Med 1963;62:1005.
41. Rabiner SF, Helbert JR, Lopas H, Friedman LH. Evaluation of stroma-free hemoglobin solution for use as a plasma expander. J Exp Med 1967;126:1127-42.
42. Stone AM, Stein T, LaFortune J, Wise L. Renal vascular effects of stroma and stroma-free hemoglobin. Surg Forum 1978;29:41-4.
43. Hess JR, Fadare SO, Tolentino LSL, et al. The intravascular persistence of crosslinked human hemoglobin. Prog Clin Biol Res 1989;319:351-7.
44. Hess JR, Wade CE, Winslow RM. Filtration-assisted exchange transfusion using ααHb, an erythrocyte substitute. J Appl Physiol 1991;70:1639-44.
45. Vlahakes GJ, Lee R, Jacobs EE Jr, et al. Hemodynamic effects and oxygen transport properties of a new blood substitute in a model of massive blood replacement. J Thorac Cardiovasc Surg 1990;100:379-88.
46. Nho K, Glower D, Bredehoeft S, et al. PEG-bovine hemoglobin: safety in a canine dehydrated hypovolemic-hemorrhagic shock model. Biomater Artif Cells Immobil Biotechnol 1992;20:511-24.
47. Wong M, Suslick KS. Sonochemically produced hemoglobin microbubbles. Proceedings of the Materials Research Society National Meeting, Symposium W2, Boston, MA, Fall 1994.
48. Mok W, Chen D-E, Mazur A. Cross-linked hemoglobins as potential plasma protein extenders. Fed Proc 1975;34:1458.
49. 2). J Biol Chem 1986;261:9929-37.
50. Keipert PE, Adeniran AJ, Kwong S, Benesch RE. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute. Transfusion 1989;29:768-73.
51. Snyder SR, Welty EV, Walder RY, et al. HbXL99α: a hemoglobin derivative that is cross-linked between the a subunits is useful as a blood substitute. Proc Natl Acad Sci USA 1987;84:7280-4.
52. Chapman KW, Snell SM, Jesse RG, et al. Pilot scale production of pyrogen-free human hemoglobin for research. Biomater Artif Cells Immobil Biotechnol 1992;20:415-21.
53. Hoffman SJ, Looker DL, Roehrich JM, et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc Natl Acad Sci USA 1990;87:8521-5.
54. Wagenbach M, ORourke K, Vitez L, et al. Synthesis of wild type and mutant human hemoglobins in saccharomyces cerevisiae. Biotechnology 1991;9:57-61.
55. Looker D, Abbott-Brown D, Cozart P, et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature 1992;356:258-60.
56. Sehgal LR, Rosen AL, Gould SA, et al. Preparation and in vitro characteristics of polymerized pyridoxalated hemoglobin. Transfusion 1983;23:158-62.
57. Sehgal LR, Gould SA, Rosen AL, et al. Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery 1984;95:433-8.
58. Sehgal LR, Sehgal HL, Rosen AL, et al. Characteristics of polymerized pyridoxylated hemoglobin. Biomater Artif Cells Artif Organs 1988;16:173-83.
59. Chang TMS. Semipermeable microcapsules. Science 1964;146:524-5.
60. Chang TMS. Semipermeable aqueous microcapsules. Thesis. McGill University, Montreal, Quebec, Canada, 1965.
61. Chang TMS. Semipermeable aqueous microcapsules ("artificial cells"): with emphasis on experiments in an extracorporeal shunt system. Trans Am Soc Artif Intern Organs 1966;12:13-9.
62. Chang TMS. Artificial cells. Monograph. Springfield, IL: Charles C Thomas, 1972.
63. Zalipsky S, Seltzer R, Menon-Rudolph S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnol Appl Biochem 1992;15:100-14.
64. Dietz NM, Joyner MJ. Haemoglobin-based blood substitutes: What's on the horizon? Ann Acad Med Singapore 1994;23(Suppl):71S-76S.
65. Estep TN, Gonder J, Bornstein I, Aono F. Immunogenicity of diaspirin cross-linked human hemoglobin solutions. Biomater Artif Cells Immobil Biotechnol 1992;20:603-9.
66. Hsia JC, Song DL, Er SS, Wong LTL. Pharmacokinetic studies in the rat on a o-raffinose polymerized human hemoglobin. Biomater Artif Cells Immobil Biotechnol 1992;20:587-95.
67. Feola M, Gonzales H, Canizaro PC, et al. Development of a bovine stroma-free hemoglobin solution as a blood substitute. Surg Gynecol Obstet 1983;157:399-408.
68. Benesch RE, Benesch R, Renthal RD, Maeda N. Affinity labeling of the polyphosphate binding site of hemoglobin. Biochemistry 1972;11:3576-82.
69. Bunn HF. Differences in the interaction of 2,3-diphosphoglycerate with certain mammalian hemoglobins. Science 1971;172:1049-50.
70. Fronticelli C, Bucci E, Orth C. Solvent regulation of oxygen affinity in hemoglobin. J Biol Chem 1984;259:10841-4.
71. DeVenuto F. Evaluation of human and bovine modified-hemoglobin solution as oxygen-carrying fluid for blood volume replacement. Biomat Artif Cells Artif Organs 1988;16:77-83.
72. Estep TN, Bechtel MK, Miller TJ, Bagdasarian A. Virus inactivation in hemoglobin solutions by heat. In: Chang TMS, Geyer RP, eds. Blood substitutes. New York Dekker, 1989;129-34.
73. Looker D, Mathews AJ, Neway JO, Stetler GL. Expression of recombinant human hemoglobin in Escherichia coli Methods Enzymol 1994;231:364-74.
74. Ogden JE, Coghlan D, Jones G, et al. Expression and assembly of functional human hemoglobin in S. cerevisiae. Biomater Artif Cells Immobil Biotechnol 1992;20:473-5.
75. O'Donnell JK, Martin MJ, Logan JS, Kumar R. Production of human hemoglobin in transgenic swine: an approach to a blood substitute. Cancer Detect Prev 1993;17:307-12.
76. Logan JS, Martin MJ. Transgenic swine as a recombinant production system for human hemoglobin. Methods Enzymol 1994;231:435-45.
77. 50 values. Crit Care Med 1979;7:380-3.
78. 2 carrier. Ann Surg 1990;211:394-8.
79. Keipert PE, Chang TMS. Effects of partial and total isovolemic exchange transfusion in fully conscious rats using pyridoxylated polyhemoglobin solution as a colloidal oxygen-delivering blood replacement fluid. Vox Sang 1987;53:7-14.
80. Chang TMS, Varma R. Effect of a single replacement of one of Ringer lactate, hypertonic saline/dextran, 7g% albumin, stroma-free hemoglobin, o-raffinose polyhemoglobin or whole blood on the long term survival of unanesthetized rats with lethal hemorrhagic shock after 67% acute blood loss. Biomater Artif Cells Immobil Biotechnol 1992;20:503-10.
81. DeVenuto F, Zegna A. Blood exchange with pyridoxalated and polymerized hemoglobin solution. Surg Gynecol Obstet 1982;155:342-6.
82. Hess JR, MacDonald VW, Winslow RM. Dehydration and shock: an animal model of hemorrhage and resuscitation of battlefield injury. Biomater Artif Cells Immobil Biotechnol 1992;20:499-502.
83. Harringer W, Hodakowski GT, Svizzero T, et al. Acute effects of massive transfusion of a bovine hemoglobin blood substitute in a canine model of hemorrhagic shock. Eur J Cardiothorac Surg 1992;6:649-54.
84. Hess JR, MacDonald VW, Brinkley WW. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 1993;74:1769-78.
85. Nees JE, Hauser CJ, Shippy C, et al. Comparison of cardiorespiratory effects of crystalline hemoglobin, whole blood, albumin, and Ringer's lactate in the resuscitation of hemorrhagic shock in dogs. Surgery 1978;83:639-47.
86. Bosman RJ, Minten J, Lu HR, et al. Free polymerized hemoglobin versus hydroxyethyl starch in resuscitation of hypovolemic dogs. Anesth Analg 1992;75:811-7.
87. Winslow RM, Murray A, Gibson CC. Oxygen equilibrium curve of concentrated hemoglobin. Methods Enzymol 1994;232:486-95.
88. Biro GP. Blood substitutes and the cardiovascular system. Biomater Artif Cells Artif Organs 1988;16:595-606.
89. Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985;232:708-16.
90. Alayash AI, Fratantoni JC, Bonaventura C, et al. Nitric oxide binding to human ferrihemoglobins cross-linked between either α or β subunits. Arch Biochem Biophys 1993;303:332-8.
91. Kida Y, Iwata S, Gyoutoku Y, et al. Vascular responsiveness to various vasoactive substances after exchange transfusion with pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) solution in anesthetized rats. Artif Organs 1991;15:5-14.
92. Katsuyama SS, Cole DJ, Drummond JC, Bradley K. Nitric oxide mediates the hypertensive response to a modified hemoglobin solution (DCLHb™) in rats. Artif Cells Blood Substit Immobil Biotechnol 1994;22:1-7.
93. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
94. Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res 1993;73:217-22.
95. Stamler JS, Loh E, Roddy M-A, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035-40.
96. G-monomethyl-L-arginine in canine basilar artery. In: Rubanyi GM, Vanhoutte PM, eds. Endothelium-derived relaxing factors. Basel: Karger, 1989:95-8.
97. Macdonald RL, Weir BKA. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991;22:971-82.
98. Hodakowski GT, Page RD, Harringer W, et al. Greater maximal myocardial oxygen delivery after hemodilution with polymerized bovine hemoglobin blood substitute. American College of Surgeons 1990 Surgical Forum, Boston, MA, 1990;XLI: 304-6.
99. Cole DJ, Schell RM, Pryzbelski RJ, et al. Focal cerebral ischemia in rats: effect of hemodilution with α-α cross-linked hemoglobin on CBF. J Cereb Blood Flow Metab 1992;12:971-6.
100. Cole DJ, Schell RM, Drummond JC, et al. Focal cerebral ischemia in rats: effect of hemodilution with α-α cross-linked hemoglobin on brain injury and edema. Can J Neurol Sci 1993;20:30-6.
101. Cole DJ, Schell RM, Drummond JC, Reynolds L. Focal cerebral ischemia in rats: effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema. Anesthesiology 1993;78:335-42.
102. Warner ME, Warner MA. Changing prevalences of co-morbid diseases in elderly surgical patients [abstract]. Anesth Analg 1995;80(suppl):S541.
103. Lee R, Atsumi N, Jacobs EE Jr, et al. Ultrapure, stroma-free, polymerized bovine hemoglobin solution: evaluation of renal toxicity. J Surg Res 1989;47:407-11.
104. Anderson B, Ostberg J. Survival rates in surgery of the aged: assessment of long-term prognosis according to coexisting diseases. Gerontol Clin 1972;14:354-60.
105. Marks DH, Brown DR, Ottinger WE, Atassi MZ. Antibody response to transfusion with pyridoxalated polymerized hemoglobin solution. Milit Med 1987;152:473-7.
106. Chang TMS, Varma R. Immunological and systemic effects of transfusions in rats using pyridoxylated hemoglobin and polyhemoglobin from homologous and heterogenous sources. Biomater Artif Cells Artif Organs 1988;16:205-15.
107. Chang TMS, Lister C, Nishiya T, Varma R. Immunological effects of hemoglobin, encapsulated hemoglobin, polyhemoglobin and conjugated hemoglobin using different immunization schedules. Biomater Artif Cells Immobil Biotechnol 1992;20:611-8.
108. Cunnington PG, Jenkins SN, Tam S-C, Wong JT-F. Oxygen-binding and immunological properties of complexes between dextran and animal hemoglobins. Biochem J 1981;193:261-6.
109. Greenburg AG, Kim HW. Evaluating new red cell substitutes: a critical analysis of toxicity models. Biomater Artif Cells Immobil Biotechnol 1992;20:575-9.
110. Ning J, Chang TMS. In vivo effects of stroma-free hemoglobin and polyhemoglobin on coagulation factors in rats. Int J Artif Organs 1990;13:509-16.
111. Reiss RF, Caballero R, Hess J. Effects of X-linked hemoglobin in in vitro platelet function. Biomater Artif Cells Immobil Biotechnol 1992;20:651-5.
112. Chang TMS, Lister CW. Assessment of blood substitutes. H. In-vitro complement activation of human plasma and blood for safety studies in research, development, industrial production and preclinical analysis. Artif Cells Blood Substit Immobil Biotechnol 1994;22:171-80.
113. Keipert PE, Gomez CL, Gonzales A, et al. Diaspirin crosslinked hemoglobin: tissue distribution and long-term excretion exchange transfusion. J Lab Clin Med 1994;123:701-11.
114. Kim HW, Chen F, Greenburg AG. A double (exchange transfusion-carbon clearance) model for testing post-resuscitation reticuloendothelial function. Biomater Artif Cells Immobil Biotechnol 1992;20:777-9.
115. Manning LR, Morgan S, Beavis RC, et al. Preparation, properties, and plasma retention of human hemoglobin derivatives: comparison of uncrosslinked carboxymethylated hemoglobin with crosslinked tetrameric hemoglobin. Proc Natl Acad Sci USA 1991;88:3329-33.
116. Feola M, Simoni J, Angelillo R, et al. Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia. Surg Gynecol Obstet 1992;174:379-86.
117. Rudolph AS. Encapsulated hemoglobin: current issues and future goals. Artif Cells Blood Substit Immobil Biotechnol 1994;22:347-60.
118. Rabinovici R, Rudolph AS, Ligler FS, et al. Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. Circ Shock 1992;37:124-33.
119. Rabinovici R, Rudolph AS, Feuerstein G. Characterization of hemodynamic, hematologic, and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, free moving rat. Circ Shock 1989;29:115-32.
120. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. Lyophilized liposome encapsulated hemoglobin: evaluation of hemodynamic, biochemical, and hematologic responses. Crit Care Med 1994;22:480-5.
121. Usuba A, Motoki R, Miyauchi Y, et al. Effect of neo red cells on the canine hemorrhagic shock model. Int J Artif Organs 1991;14:739-44.
122. Farmer MC, Johnson SA, Beissinger RL, et al. Liposome-encapsulated hemoglobin: a synthetic red cell. Adv Exp Med Biol 1988;238:161-70.
123. Tsuchida E. Synthesis and characterization of artificial red cell (ARC). Biomater Artif Cells Immobil Biotechnol 1992;20:337-44.
124. Djordjevich L, Ivankovich AD. Progress in development of synthetic erythrocytes made by encapsulation of hemoglobin. Adv Exp Med Biol 1988;238:171-97.
125. 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc Natl Acad Sci USA 1991;88:10976-80.
126. Gaber BP, Farmer MC. Encapsulation of hemoglobin in phospholipid vesicles: preparation and properties of a red cell surrogate. In: Brewer GJ, ed. The red cell: Sixth Ann Arbor Conference. New York: Alan R. Liss, 1984:179-90.
127. Clark LC Jr, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966;152:1755-6.
128. Millard RW. Oxygen solubility, rheology and hemodynamics of perfluorocarbon emulsion blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994;22:235-44.
129. Faithfull NS. Mechanisms and efficacy of fluorochemical oxygen transport and delivery. Artif Cells Blood Substit Immobil Biotechnol 1994;22:181-97.
130. Biro GP. Perfluorocarbon-based red blood cell substitutes. Transfus Med Rev 1993;7:84-95.
131. Kerins DM. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci 1994;307:218-21.
132. Spence RK, McCoy S, Costabile J, et al. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients. Crit Care Med 1990;18:1227-30.
133. Tremper KK, Friedman AE, Levine EM, et al. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N Engl J Med 1982;307:277-83.
134. Hubmayr RD, Rodarte JR. Acute and long-term effects of Fluosol-DA 20% on respiratory system mechanics and diffusion capacity in dogs. J Crit Care 1988;3:232-9.
135. Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 1982;59:1299-1304.
136. Riess JG. Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs 1984;8:44-56.
137. Riess JG. Blood substitutes: where do we stand with the fluorocarbon approach? Curr Surg 1988;45:365-70.
138. Lowe KC, Bentley PK. Retention of perfluorochemicals in rat liver and spleen. Biomater Artif Cells Immobil Biotechnol 1992;20:1029-31.
139. Armstrong FH, Lowe KC. Effects of emulsified perfluorochemicals on liver cytochromes P-450 in rats. Comp Biochem Physiol [C] 1989;94:345-9.
140. Hoke JF, Ravis WR. Effect of a perfluorochemical erythrocyte substitute on the in vitro metabolism of lidocaine using rat liver slices. Res Commun Chem Pathol Pharmacol 1991;73:333-53.
141. Shah IG, Parsons DL. Human albumin binding of tamoxifen in the presence of a perfluorochemical erythrocyte substitute. J Pharm Pharmacol 1991;43:790-3.
142. Zarif L, Reiss JG, Pucci B, Pavia AA. Biocompatibility of alkyl and perfluoralkyl telomeric surfactants derived from THAM. Biomater Artif Cells Immobil Biotechnol 1993;21:597-608.
143. Rudolph AS. The freeze-dried preservation of liposome encapsulated hemoglobin: a potential blood substitute. Cryobiology 1988;25:277-84.
144. Bucala R, Kawakami M, Cerami A. Cytotoxicity of a perfluorocarbon blood substitute to macrophages in vitro. Science 1983;220:965-7.
145. Geyer RP. Fluorocarbon-polyol artificial blood substitutes. N Engl J Med 1973;289:1077-82.
146. Flaim SF, Hazard DR, Hogan J, Peters RM. Characterization and mechanism of side-effects of Oxygent™ HT (highly concentrated fluorocarbon emulsion) in swine. Biomater Artif Cells Immobil Biotechnol 1991;19:383.
147. Lustig R, McIntosh-Lowe N, Rose C, et al. Phase I/II study of fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck. Int J Radiat Oncol Biol Phys 1989;16:1587-93.
148. Lustig R, Lowe N, Prosnitz L, et al. Fluosol and oxygen breathing as an adjuvant to radiation therapy in the treatment of locally advanced non-small cell carcinoma of the lung: results of a phase I/II study. Int J Radiat Oncol Biol Phys 1990;19:97-102.
149. Evans RG, Kimler BF, Morantz RA, et al. A phase I/II study of the use of Fluosol® as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys 1990;19:415-20.
150. Owings DV, Kruskall MS, Thurer RL, Donovan LM. Autologous blood donations prior to elective cardiac surgery. JAMA 1989;262:1963-8.
151. Atlas SJ, Singer DE, Skates SJ. Changing blood use in the AIDS era: the case of elective hip surgery. Transfusion 1994;34:386-91.
152. Goodnough LT, Johnston MFM, Toy PTCY. The variability of transfusion practice in coronary artery bypass surgery. JAMA 1991;265:86-90.
153. Goodnough LT, Grishaber JE, Monk TG, Catalona WJ. Acute preoperative hemodilution in patients undergoing radical prostatectomy: a case study analysis of efficacy. Anesth Analg 1994;78:932-7.
154. Stehling L, Simon TL. The red blood cell transfusion trigger: physiology and clinical studies. Arch Pathol Lab Med 1994;118:429-34.
155. American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:403-6.
156. Spahn DR, Leone BJ, Reves JG, Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg 1994;78:1000-21.
157. Stehling L, Zauder HL. Controversies in transfusion medicine. Perioperative hemodilution: Pro. Transfusion 1994;34:265-8.
158. AuBuchon JP, Birkmeyer JD. Controversies in transfusion medicine. Is autologous blood transfusion worth the cost? Con. Transfusion 1994;34:79-83.
159. Gillon J. Controversies in transfusion medicine. Acute normovolemic hemodilution in elective major surgery: Con. Transfusion 1994;34:269-71.
160. Stone JJ, Piccione W, Berrizbeitia LD, et al. Hemodynamic, metabolic, and morphological effects of cardiopulmonary bypass with a fluorocarbon priming solution. Ann Thorac Surg 1986;41:419-24.
161. Slanetz PJ, Lee R, Page R, et al. Hemoglobin blood substitutes in extended preoperative autologous blood donation: an experimental study. Surgery 1994;115:246-54.
162. Floyd TF, Boroughs A, Garvey C, et al. Intestinal ischemia: treatment by peritoneal lavage with oxygenated perfluorochemical. J Pediatr Surg 1987;22:1191-7.
163. Oldham KT, Guice KS, Gore D, et al. Treatment of intestinal ischemia with oxygenated intraluminal perfluorocarbons. Am J Surg 1987;153:291-4.
164. Ricci JL, Sloviter HA, Ziegler MM. Intestinal ischemia: reduction of mortality utilizing intraluminal perfluorochemical. Am J Surg 1985;149:84-90.
165. Takahashi F, Tsai T-M, Fleming PE, Oden L. The ability of oxygenated fluorocarbon solution to minimize ischemic skeletal muscle injury. Plast Reconstr Surg 1987;80:582-90.
166. Yabe Y, Ishiguro N, Shimizu T, et al. Morphologic and metabolic study of the effect of oxygenated perfluorochemical perfusion on amputated rabbit limbs. J Reconstr Microsurg 1994;10:185-91.
167. Ogilby JD, Noma S, DiLoretto G, Stets G. Preservation of myocardial function during ischemia with intracoronary perfluoroocytlbromide (Oxygen™). Biomater Artif Cells Immobilization Biotechnol 1992;20:973-7.
168. McKenzie JE, Cost EA, Scandling DM, Savage RW. Effects of diasprin cross-linked hemoglobin (DCLHb) on cardiac function and ECG in the swine. Biomater Artif Cells Immobil Biotechnol 1992;20:683-7.
169. Wall TC, Califf RM, Blankenship J, et al. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the thrombolysis and angioplasty in myocardial infarction 9 trial. TAMI 9 Research Group. Circulation 1994;90:114-20.
170. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32.
171. Gmethyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990;172:1132-8.
172. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993;41:77-81.
173. 1. J Immunol 1987;139:518-25.
174. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to Interferon γ in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 1990;82:772-6.
175. Gross SS, Jaffe EA, Levi R, Kilbourn RG. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun 1991;178:823-9.
176. Ziegler EJ, Douglas H, Sherman JE, et al. Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase deficient mutant. J Immunol 1973;111:433-8.
177. Heumann D, Baumgarther JD, Jacot-Guillarmod H, Glauser MP. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides. J Infect Dis 1991;163:762-8.
178. Krieger JI, Fletcher RC, Siegel SA, et al. Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. J Infect Dis 1993;167:865-75.
179. Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 1992;84:827-31.
180. Nava E, Palmer RJM, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 1991;338:1555-7.
181. G-monomethyl-L-arginine. J Cardiovasc Pharmacol 1992;20:S132-4.
182. Hollenberg SM, Cunnion RE, Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 1993;264:H660-3.
183. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-8.
184. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-9.
185. Kilbourn RG, Joly G, Cashon B, et al. Cell-free hemoglobin reverses the endotoxin-mediated hyporesponsivity of rat aortic rings to α-adrenergic agents. Biochem Biophys Res Commun 1994;199:155-62.
186. Natanson C, Hoffman WD, Suffredini AF, et al. Selected treatment strategies of septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-83.
187. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
188. Gatenby RA, Coia LR, Richter MP, et al. Oxygen tension in human tumors: In vivo mapping using CT-guided probes. Radiology 1985;156:211-4.
189. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-8.
190. Kennedy KA, Rockwell S, Sartorelli AC. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 1980;40:2356-60.
191. Koch CJ, Kruuv J, Frey HE, Snyder RA. Plateau phase in growth induced by hypoxia. Int J Radiat Biol 1973;23:67-74.
192. Bedford JS, Mitchell JB. The effect of hypoxia on the growth and radiation response of mammalian cells in culture. Br J Radiol 1974;47:687-96.
193. Born R, Hug O, Trott KR. The effect of prolonged hypoxia on growth and viability of Chinese hamster cells. Int J Radiat Oncol Biol Phys 1976;1:687-97.
194. Song CW, Zhang WL, Pence DM, et al. Increased radiosensitivity of tumors by perfluorochemicals and carbogen. Int J Radiat Oncol Biol Phys 1985;11:1833-6.
195. Martin DF, Porter EA, Fisher JJ, Rockwell S. Effect of a perfluorochemical emulsion on the radiation response of BA1112 rhabdomyosarcomas. Radiat Res 1987;112:45-53.
196. 2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen. Cancer Res 1987;47:442-6.
197. Teicher BA, Rose CM. Perfluorochemical emulsions can increase tumor radiosensitivity. Science 1984;223:934-6.
198. Rockwell S, Mate TP, Irvin CG, Nierenburg M. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 1986;12:1315-8.
199. Lee I, Levitt SH, Song CW. Effects of Fluosol DA 20% and carbogen on the radioresponse of SCK tumors and skin of A/J mice. Radiat Res 1987;112:173-82.
200. Fratantoni JC. Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Transfusion 1991;31:369-71.
201. Fratantoni JC. Point to consider on efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers. Transfusion 1994;34:712-3.